Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Organization

NCI

Type

NIH

Link

Standard due dates apply

Number

PAR-21-290

Comments

Open Date (Earliest Submission Date): 9/5/21. LOI due 30 days prior to the application due date.

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.